Foralumab is a fully human anti-CD3 monoclonal antibody originally discovered and developed through advanced biopharmaceutical research, and subsequently in-licensed, formulated, and clinically advanced by Tiziana Life Sciences. The specialized nasal spray formulation and alternative route delivery methods for the drug have been progressed in close scientific collaboration with premier academic medical institutions, such as the Brigham and Women's Hospital neurology research groups, utilizing specialized contract manufacturing organizations to produce clinical trial supplies under strict regulatory standards.